Kamada (NASDAQ:KMDA) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Kamada from “hold” to “strong-buy,” while the broader analyst consensus remains “Buy” with a $13.00 price target.
• Kamada reported quarterly EPS of $0.16, exceeding the $0.11 estimate, and revenue of $54.92 million, above expectations of $50.84 million.
• KMDA opened at $7.58, with a market capitalization of approximately $435.9 million; institutional investors own 20.38% of the company’s shares.

Kamada (NASDAQ:KMDA - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "strong-buy" rating in a report issued on Saturday.

KMDA has been the topic of several other reports. Weiss Ratings cut Kamada from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday, June 25th. Benchmark restated a "buy" rating on shares of Kamada in a report on Tuesday, July 21st. Finally, William Blair set a $15.00 price objective on Kamada in a research note on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $13.00.

Kamada Stock Performance

KMDA opened at $7.58 on Friday. The stock has a market capitalization of $435.93 million, a price-to-earnings ratio of 19.95, a PEG ratio of 0.64 and a beta of 0.86. The company has a fifty day moving average of $7.22 and a 200 day moving average of $7.96. Kamada has a fifty-two week low of $6.50 and a fifty-two week high of $9.35.

Kamada (NASDAQ:KMDA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.11 by $0.05. Kamada had a net margin of 11.60% and a return on equity of 8.37%. The business had revenue of $54.92 million for the quarter, compared to analysts' expectations of $50.84 million. On average, equities research analysts forecast that Kamada will post 0.45 earnings per share for the current year.

Institutional Trading of Kamada

Large investors have recently made changes to their positions in the business. NewEdge Advisors LLC lifted its holdings in shares of Kamada by 9.2% in the 4th quarter. NewEdge Advisors LLC now owns 57,538 shares of the biotechnology company's stock valued at $406,000 after acquiring an additional 4,870 shares during the last quarter. JPMorgan Chase & Co. grew its position in Kamada by 43.6% in the third quarter. JPMorgan Chase & Co. now owns 40,984 shares of the biotechnology company's stock worth $284,000 after acquiring an additional 12,442 shares in the last quarter. Man Group plc increased its stake in Kamada by 19.9% during the fourth quarter. Man Group plc now owns 34,294 shares of the biotechnology company's stock worth $242,000 after acquiring an additional 5,684 shares during the last quarter. Jump Financial LLC bought a new stake in Kamada during the second quarter worth approximately $219,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Kamada during the first quarter valued at approximately $206,000. 20.38% of the stock is currently owned by institutional investors.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source